Regeneron Pharmaceuticals, Inc. (REGN) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 3.61B | 3.88B | 3.75B | 3.68B | 3.03B | 3.79B | 3.72B | 3.55B | 3.15B | 3.43B | 3.36B | 3.16B |
| Revenue Growth % | 19.04% | 2.51% | 0.9% | 3.62% | -3.7% | 10.33% | 10.65% | 12.32% | -0.54% | 0.58% | 14.53% | 10.53% |
| Cost of Goods Sold | 669.4M | 584.6M | 521.6M | 530.2M | 464.3M | 565.4M | 491.1M | 480.2M | 433.8M | 629.1M | 541.8M | 508M |
| COGS % of Revenue | 18.57% | 15.05% | 13.89% | 14.42% | 15.33% | 14.92% | 13.2% | 13.54% | 13.79% | 18.32% | 16.11% | 16.09% |
| Gross Profit | 2.94B | 3.3B | 3.23B | 3.15B | 2.56B | 3.22B | 3.23B | 3.07B | 2.71B | 2.81B | 2.82B | 2.65B |
| Gross Margin % | 81.43% | 84.95% | 86.11% | 85.58% | 84.67% | 85.08% | 86.8% | 86.46% | 86.21% | 81.68% | 83.89% | 83.91% |
| Gross Profit Growth % | 14.49% | 2.35% | 0.1% | 2.56% | -5.41% | 14.92% | 14.49% | 15.73% | 4.07% | -3.52% | 11.68% | 6.61% |
| Operating Expenses | 2.29B | 2.42B | 2.21B | 2.07B | 1.97B | 2.23B | 2.05B | 2B | 1.96B | 1.75B | 1.61B | 1.63B |
| OpEx % of Revenue | 63.6% | 62.3% | 58.76% | 56.21% | 65.13% | 58.95% | 55.1% | 56.31% | 62.31% | 51.09% | 47.88% | 51.73% |
| Selling, General & Admin | 647.7M | 775M | 657.8M | 634.2M | 633M | 792.2M | 714.4M | 758.8M | 689M | 704.4M | 640.5M | 652M |
| SG&A % of Revenue | 17.96% | 19.95% | 17.52% | 17.25% | 20.9% | 20.91% | 19.2% | 21.39% | 21.91% | 20.51% | 19.05% | 20.65% |
| Research & Development | 1.65B | 1.63B | 1.56B | 1.43B | 1.34B | 1.43B | 1.33B | 1.22B | 1.26B | 1.05B | 969.9M | 982.2M |
| R&D % of Revenue | 45.64% | 41.86% | 41.5% | 38.95% | 44.23% | 37.63% | 35.68% | 34.5% | 39.92% | 30.59% | 28.84% | 31.1% |
| Other Operating Expenses | 0 | 1000K | -1000K | 0 | 0 | 1000K | 1000K | 1000K | 1000K | -500K | -500K | -600K |
| Operating Income | 642.9M | 879.9M | 1.03B | 1.08B | 591.7M | 990.2M | 1.18B | 1.07B | 751.4M | 1.05B | 1.21B | 1.02B |
| Operating Margin % | 17.83% | 22.65% | 27.35% | 29.37% | 19.54% | 26.13% | 31.7% | 30.15% | 23.89% | 30.59% | 36.01% | 32.19% |
| Operating Income Growth % | 8.65% | -11.14% | -12.95% | 0.93% | -21.25% | -5.76% | -2.6% | 5.22% | -25.07% | -20.12% | -1.04% | -22.22% |
| EBITDA | 766.1M | 1.02B | 1.16B | 1.21B | 718.6M | 1.12B | 1.3B | 1.19B | 865.5M | 1.16B | 1.32B | 1.12B |
| EBITDA Margin % | 21.25% | 26.39% | 30.99% | 33.04% | 23.73% | 29.47% | 34.97% | 33.56% | 27.52% | 33.88% | 39.15% | 35.45% |
| EBITDA Growth % | 6.61% | -8.21% | -10.58% | 2.04% | -16.97% | -4.05% | -1.15% | 6.31% | -21.48% | -17.79% | 0.01% | -18.95% |
| D&A (Non-Cash Add-back) | 123.2M | 145M | 136.7M | 135.1M | 126.9M | 126.4M | 121.7M | 120.7M | 114.1M | 113M | 105.4M | 103.1M |
| EBIT | 844.1M | 1.06B | 1.78B | 1.52B | 913.7M | 968.6M | 1.51B | 1.64B | 716.8M | 1.17B | 1.13B | 1.1B |
| Net Interest Income | 170.6M | 181.1M | 155.8M | 171.2M | 164.8M | 172.6M | 173.6M | 164.6M | 145.4M | 130.4M | 115.9M | 99.4M |
| Interest Income | 183.5M | 193.3M | 175.1M | 174.8M | 173.5M | 183.1M | 187.4M | 179.4M | 161.5M | 148.7M | 133.7M | 118.3M |
| Interest Expense | 12.9M | 12.2M | 19.3M | 3.6M | 8.7M | 10.5M | 13.8M | 14.8M | 16.1M | 18.3M | 17.8M | 18.9M |
| Other Income/Expense | 188.3M | 163.8M | 736.5M | 439.2M | 313.3M | -32.1M | 313.5M | 558.5M | -50.7M | 96.9M | -100.2M | 66.4M |
| Pretax Income | 831.2M | 1.04B | 1.76B | 1.52B | 905M | 958.1M | 1.49B | 1.63B | 700.7M | 1.15B | 1.11B | 1.08B |
| Pretax Margin % | 23.05% | 26.87% | 46.97% | 41.32% | 29.88% | 25.29% | 40.13% | 45.9% | 22.28% | 33.42% | 33.03% | 34.29% |
| Income Tax | 104M | 199.1M | 303.3M | 127.1M | 96.3M | 40.4M | 152.4M | 195.8M | -21.3M | -12M | 103M | 114.5M |
| Effective Tax Rate % | 12.51% | 19.08% | 17.2% | 8.37% | 10.64% | 4.22% | 10.21% | 12.03% | -3.04% | -1.05% | 9.27% | 10.57% |
| Net Income | 727.2M | 844.6M | 1.46B | 1.39B | 808.7M | 917.7M | 1.34B | 1.43B | 722M | 1.16B | 1.01B | 968.4M |
| Net Margin % | 20.17% | 21.74% | 38.89% | 37.86% | 26.7% | 24.22% | 36.03% | 40.38% | 22.96% | 33.77% | 29.97% | 30.66% |
| Net Income Growth % | -10.08% | -7.97% | 8.91% | -2.84% | 12.01% | -20.86% | 33.02% | 47.9% | -11.71% | -3.13% | -23.4% | 13.65% |
| Net Income (Continuing) | 727.2M | 844.6M | 1.46B | 1.39B | 808.7M | 917.7M | 1.34B | 1.43B | 722M | 1.16B | 1.01B | 968.4M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 6.75 | 7.86 | 13.62 | 12.81 | 7.27 | 8.06 | 11.54 | 12.41 | 6.27 | 10.19 | 8.89 | 8.50 |
| EPS Growth % | -7.15% | -2.48% | 18.02% | 3.22% | 15.95% | -20.9% | 29.81% | 46% | -12.55% | -2.95% | -23.76% | 13.79% |
| EPS (Basic) | 6.99 | 8.21 | 14.09 | 13.24 | 7.58 | 8.53 | 12.40 | 13.25 | 6.70 | 10.88 | 9.48 | 9.05 |
| Diluted Shares Outstanding | 107.7M | 107.5M | 107.2M | 108.6M | 111.2M | 113.8M | 116.2M | 115.4M | 115.1M | 113.8M | 113.4M | 113.9M |
| Basic Shares Outstanding | 104M | 102.9M | 103.62M | 105.1M | 106.7M | 107.9M | 108.1M | 108.1M | 107.8M | 106.6M | 106.3M | 107M |
| Dividend Payout Ratio | 13.45% | 10.98% | 6.25% | 6.65% | 11.6% | - | - | - | - | - | - | - |